RAS wild-type
1 drugsPredictive biomarker for patient selection in 1 indication
1
Approved Drugs
1
Indications
1
Companies
RAS wild-type is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 1 indication including Metastatic Colorectal Cancer. Explore the targeted therapies, indications, testing methods, and companies developing RAS wild-type drugs below.
Search RAS wild-type Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting RAS wild-type
| Drug | Company | Therapeutic Area |
|---|---|---|
| VECTIBIX | Amgen | Oncology |
RAS wild-type Indications
Metastatic Colorectal Cancer